Clinical Reviews in Allergy & Immunology

, Volume 45, Issue 2, pp 217–226

The Implication of Vitamin D and Autoimmunity: a Comprehensive Review

  • Chen-Yen Yang
  • Patrick S. C. Leung
  • Iannis E. Adamopoulos
  • M. Eric Gershwin
Article

Abstract

Historically, vitamin D has been associated with the regulation of bone metabolism. However, increasing evidence demonstrates a strong association between vitamin D signaling and many biological processes that regulate immune responses. The discovery of the vitamin D receptor in multiple immune cell lineages, such as monocytes, dendritic cells, and activated T cells credits vitamin D with a novel role in modulating immunological functions and its subsequent role in the development or prevention of autoimmune diseases. In this review we, discuss five major areas in vitamin D biology of high immunological significance: (1) the metabolism of vitamin D; (2) the significance of vitamin D receptor polymorphisms in autoimmune diseases, such as multiple sclerosis, type 1 diabetes mellitus, and systemic lupus erythematosus; (3) vitamin D receptor transcriptional regulation of immune cell lineages, including Th1, Th17, Th2, regulatory T, and natural killer T cells; (4) the prevalence of vitamin D insufficiency/deficiency in patients with multiple sclerosis, type 1 diabetes mellitus, and systemic lupus erythematosus; and finally, (5) the therapeutic effects of vitamin D supplementation on disease severity and progression.

Keywords

Vitamin D Autoimmunity Multiple sclerosis Type 1 diabetes mellitus Systemic lupus erythematosus 

References

  1. 1.
    Holick MF, Chen TC (2008) Vitamin D deficiency: a worldwide problem with health consequences. Am J Clin Nutr 87:1080S–1086SPubMedGoogle Scholar
  2. 2.
    Agmon-Levin N, Kivity S, Tzioufas AG et al (2012) Low levels of vitamin-D are associated with neuropathy and lymphoma among patients with Sjogren’s syndrome. J Autoimmun 39:234–239PubMedCrossRefGoogle Scholar
  3. 3.
    Giovannucci E, Liu Y, Rimm EB et al (2006) Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 98:451–459PubMedCrossRefGoogle Scholar
  4. 4.
    Giovannucci E (2009) Vitamin D and cancer incidence in the Harvard cohorts. Ann Epidemiol 19:84–88PubMedCrossRefGoogle Scholar
  5. 5.
    Twig G, Shina A, Amital H, Shoenfeld Y (2012) Pathogenesis of infertility and recurrent pregnancy loss in thyroid autoimmunity. J Autoimmun 38:J275–J281PubMedCrossRefGoogle Scholar
  6. 6.
    Anderson JL, May HT, Horne BD et al (2010) Relation of vitamin D deficiency to cardiovascular risk factors, disease status, and incident events in a general healthcare population. Am J Cardiol 106:963–968PubMedCrossRefGoogle Scholar
  7. 7.
    Sood A, Arora R (2010) Vitamin D deficiency and its correlations with increased cardiovascular incidences. Am J Ther 17:e105–e109PubMedGoogle Scholar
  8. 8.
    Qazi RA, Martin KJ (2012) Vitamin D in kidney disease: pathophysiology and the utility of treatment. Rheum Dis Clin N Am 38:115–123CrossRefGoogle Scholar
  9. 9.
    Pittas AG, Dawson-Hughes B (2010) Vitamin D and diabetes. J Steroid Biochem Mol Biol 121:425–429PubMedCrossRefGoogle Scholar
  10. 10.
    Cantorna MT, Mahon BD (2005) D-hormone and the immune system. J Rheumatol Suppl 76:11–20PubMedGoogle Scholar
  11. 11.
    Holick MF (2011) Vitamin D: evolutionary, physiological and health perspectives. Curr Drug Targets 12:4–18PubMedCrossRefGoogle Scholar
  12. 12.
    Arnson Y, Amital H, Agmon-Levin N et al (2011) Serum 25-OH vitamin D concentrations are linked with various clinical aspects in patients with systemic sclerosis: a retrospective cohort study and review of the literature. Autoimmun Rev 10:490–494PubMedCrossRefGoogle Scholar
  13. 13.
    Hajas A, Sandor J, Csathy L et al (2011) Vitamin D insufficiency in a large MCTD population. Autoimmun Rev 10:317–324PubMedCrossRefGoogle Scholar
  14. 14.
    Holick MF, MacLaughlin JA, Clark MB et al (1980) Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science 210:203–205PubMedCrossRefGoogle Scholar
  15. 15.
    Jones G, Strugnell SA, DeLuca HF (1998) Current understanding of the molecular actions of vitamin D. Physiol Rev 78:1193–1231PubMedGoogle Scholar
  16. 16.
    Haussler MR, Whitfield GK, Haussler CA et al (1998) The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 13:325–349PubMedCrossRefGoogle Scholar
  17. 17.
    Smolders J, Peelen E, Thewissen M et al (2009) The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun Rev 8:621–626PubMedCrossRefGoogle Scholar
  18. 18.
    Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP (2004) Genetics and biology of vitamin D receptor polymorphisms. Gene 338:143–156PubMedCrossRefGoogle Scholar
  19. 19.
    Colin EM, Weel AE, Uitterlinden AG et al (2000) Consequences of vitamin D receptor gene polymorphisms for growth inhibition of cultured human peripheral blood mononuclear cells by 1, 25-dihydroxyvitamin D3. Clin Endocrinol (Oxf) 52:211–216CrossRefGoogle Scholar
  20. 20.
    van Etten E, Verlinden L, Giulietti A et al (2007) The vitamin D receptor gene FokI polymorphism: functional impact on the immune system. Eur J Immunol 37:395–405PubMedCrossRefGoogle Scholar
  21. 21.
    Orton SM, Morris AP, Herrera BM et al (2008) Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr 88:441–447PubMedGoogle Scholar
  22. 22.
    Smolders J, Damoiseaux J, Menheere P, Tervaert JW, Hupperts R (2009) Fok-I vitamin D receptor gene polymorphism (rs10735810) and vitamin D metabolism in multiple sclerosis. J Neuroimmunol 207:117–121PubMedCrossRefGoogle Scholar
  23. 23.
    Monticielo OA, Brenol JC, Chies JA et al (2012) The role of BsmI and FokI vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D in Brazilian patients with systemic lupus erythematosus. Lupus 21:43–52PubMedCrossRefGoogle Scholar
  24. 24.
    Ban Y, Taniyama M, Yanagawa T et al (2001) Vitamin D receptor initiation codon polymorphism influences genetic susceptibility to type 1 diabetes mellitus in the Japanese population. BMC Med Genet 2:7PubMedCrossRefGoogle Scholar
  25. 25.
    Fassbender WJ, Goertz B, Weismuller K et al (2002) VDR gene polymorphisms are overrepresented in german patients with type 1 diabetes compared to healthy controls without effect on biochemical parameters of bone metabolism. Horm Metab Res 34:330–337PubMedCrossRefGoogle Scholar
  26. 26.
    Gyorffy B, Vasarhelyi B, Krikovszky D et al (2002) Gender-specific association of vitamin D receptor polymorphism combinations with type 1 diabetes mellitus. Eur J Endocrinol 147:803–808PubMedCrossRefGoogle Scholar
  27. 27.
    Audi L, Marti G, Esteban C et al (2004) VDR gene polymorphism at exon 2 start codon (FokI) may have influenced Type 1 diabetes mellitus susceptibility in two Spanish populations. Diabet Med 21:393–394PubMedCrossRefGoogle Scholar
  28. 28.
    Capoluongo E, Pitocco D, Concolino P et al (2006) Slight association between type 1 diabetes and “ff” VDR FokI genotype in patients from the Italian Lazio Region. Lack of association with diabetes complications. Clin Biochem 39:888–892PubMedCrossRefGoogle Scholar
  29. 29.
    Lemos MC, Fagulha A, Coutinho E et al (2008) Lack of association of vitamin D receptor gene polymorphisms with susceptibility to type 1 diabetes mellitus in the Portuguese population. Hum Immunol 69:134–138PubMedCrossRefGoogle Scholar
  30. 30.
    Panierakis C, Goulielmos G, Mamoulakis D, Petraki E, Papavasiliou E, Galanakis E (2009) Vitamin D receptor gene polymorphisms and susceptibility to type 1 diabetes in Crete, Greece. Clin Immunol 133:276–281PubMedCrossRefGoogle Scholar
  31. 31.
    Gogas Yavuz D, Keskin L, Kiyici S et al (2011) Vitamin D receptor gene BsmI, FokI, ApaI, TaqI polymorphisms and bone mineral density in a group of Turkish type 1 diabetic patients. Acta Diabetol 48:329–336PubMedCrossRefGoogle Scholar
  32. 32.
    Mohammadnejad Z, Ghanbari M, Ganjali R et al (2012) Association between vitamin D receptor gene polymorphisms and type 1 diabetes mellitus in Iranian population. Mol Biol Rep 39:831–837PubMedCrossRefGoogle Scholar
  33. 33.
    Huang CM, Wu MC, Wu JY, Tsai FJ (2002) No association of vitamin D receptor gene start codon fok 1 polymorphisms in Chinese patients with systemic lupus erythematosus. J Rheumatol 29:1211–1213PubMedGoogle Scholar
  34. 34.
    Tajouri L, Ovcaric M, Curtain R et al (2005) Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population. J Neurogenet 19:25–38PubMedCrossRefGoogle Scholar
  35. 35.
    Simon KC, Munger KL, Xing Y, Ascherio A (2010) Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Mult Scler 16:133–138PubMedCrossRefGoogle Scholar
  36. 36.
    Fukazawa T, Yabe I, Kikuchi S et al (1999) Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J Neurol Sci 166:47–52PubMedCrossRefGoogle Scholar
  37. 37.
    Chang TJ, Lei HH, Yeh JI et al (2000) Vitamin D receptor gene polymorphisms influence susceptibility to type 1 diabetes mellitus in the Taiwanese population. Clin Endocrinol (Oxf) 52:575–580CrossRefGoogle Scholar
  38. 38.
    Ozaki Y, Nomura S, Nagahama M, Yoshimura C, Kagawa H, Fukuhara S (2000) Vitamin-D receptor genotype and renal disorder in Japanese patients with systemic lupus erythematosus. Nephron 85:86–91PubMedCrossRefGoogle Scholar
  39. 39.
    Niino M, Fukazawa T, Yabe I, Kikuchi S, Sasaki H, Tashiro K (2000) Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J Neurol Sci 177:65–71PubMedCrossRefGoogle Scholar
  40. 40.
    Huang CM, Wu MC, Wu JY, Tsai FJ (2002) Association of vitamin D receptor gene BsmI polymorphisms in Chinese patients with systemic lupus erythematosus. Lupus 11:31–34PubMedCrossRefGoogle Scholar
  41. 41.
    Taverna MJ, Sola A, Guyot-Argenton C et al (2002) Taq I polymorphism of the vitamin D receptor and risk of severe diabetic retinopathy. Diabetologia 45:436–442PubMedCrossRefGoogle Scholar
  42. 42.
    Shimada A, Kanazawa Y, Motohashi Y et al (2008) Evidence for association between vitamin D receptor BsmI polymorphism and type 1 diabetes in Japanese. J Autoimmun 30:207–211PubMedCrossRefGoogle Scholar
  43. 43.
    Luo XY, Yang MH, Wu FX et al (2012) Vitamin D receptor gene BsmI polymorphism B allele, but not BB genotype, is associated with systemic lupus erythematosus in a Han Chinese population. Lupus 21:53–59PubMedCrossRefGoogle Scholar
  44. 44.
    Sakulpipatsin W, Verasertniyom O, Nantiruj K, Totemchokchyakarn K, Lertsrisatit P, Janwityanujit S (2006) Vitamin D receptor gene BsmI polymorphisms in Thai patients with systemic lupus erythematosus. Arthritis Res Ther 8:R48PubMedCrossRefGoogle Scholar
  45. 45.
    Smolders J, Damoiseaux J, Menheere P, Tervaert JW, Hupperts R (2009) Association study on two vitamin D receptor gene polymorphisms and vitamin D metabolites in multiple sclerosis. Ann N Y Acad Sci 1173:515–520PubMedCrossRefGoogle Scholar
  46. 46.
    Abbasi M, Rezaieyazdi Z, Afshari JT, Hatef M, Sahebari M, Saadati N (2010) Lack of association of vitamin D receptor gene BsmI polymorphisms in patients with systemic lupus erythematosus. Rheumatol Int 30:1537–1539PubMedCrossRefGoogle Scholar
  47. 47.
    Sioka C, Papakonstantinou S, Markoula S et al (2011) Vitamin D receptor gene polymorphisms in multiple sclerosis patients in northwest Greece. J Negat Results Biomed 10:3PubMedCrossRefGoogle Scholar
  48. 48.
    Cox MB, Ban M, Bowden NA, Baker A, Scott RJ, Lechner-Scott J (2012) Potential association of vitamin D receptor polymorphism Taq1 with multiple sclerosis. Mult Scler 18:16–22PubMedCrossRefGoogle Scholar
  49. 49.
    Adorini L, Penna G (2008) Control of autoimmune diseases by the vitamin D endocrine system. Nat Clin Pract Rheumatol 4:404–412PubMedCrossRefGoogle Scholar
  50. 50.
    Szodoray P, Nakken B, Gaal J et al (2008) The complex role of vitamin D in autoimmune diseases. Scand J Immunol 68:261–269PubMedCrossRefGoogle Scholar
  51. 51.
    Cutolo M, Pizzorni C, Sulli A (2011) Vitamin D endocrine system involvement in autoimmune rheumatic diseases. Autoimmun Rev 11:84–87PubMedCrossRefGoogle Scholar
  52. 52.
    Peelen E, Knippenberg S, Muris AH et al (2011) Effects of vitamin D on the peripheral adaptive immune system: a review. Autoimmun Rev 10:733–743PubMedCrossRefGoogle Scholar
  53. 53.
    Bhalla AK, Amento EP, Clemens TL, Holick MF, Krane SM (1983) Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J Clin Endocrinol Metab 57:1308–1310PubMedCrossRefGoogle Scholar
  54. 54.
    Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC (1983) 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 221:1181–1183PubMedCrossRefGoogle Scholar
  55. 55.
    Veldman CM, Cantorna MT, DeLuca HF (2000) Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Arch Biochem Biophys 374:334–338PubMedCrossRefGoogle Scholar
  56. 56.
    Deluca HF, Cantorna MT (2001) Vitamin D: its role and uses in immunology. FASEB J 15:2579–2585PubMedCrossRefGoogle Scholar
  57. 57.
    Alroy I, Towers TL, Freedman LP (1995) Transcriptional repression of the interleukin-2 gene by vitamin D3: direct inhibition of NFATp/AP-1 complex formation by a nuclear hormone receptor. Mol Cell Biol 15:5789–5799PubMedGoogle Scholar
  58. 58.
    Lemire JM, Archer DC, Beck L, Spiegelberg HL (1995) Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 125:1704S–1708SPubMedGoogle Scholar
  59. 59.
    Cippitelli M, Santoni A (1998) Vitamin D3: a transcriptional modulator of the interferon-gamma gene. Eur J Immunol 28:3017–3030PubMedCrossRefGoogle Scholar
  60. 60.
    Rigby WF, Stacy T, Fanger MW (1984) Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J Clin Invest 74:1451–1455PubMedCrossRefGoogle Scholar
  61. 61.
    Lemire JM, Adams JS, Kermani-Arab V, Bakke AC, Sakai R, Jordan SC (1985) 1,25-Dihydroxyvitamin D3 suppresses human T helper/inducer lymphocyte activity in vitro. J Immunol 134:3032–3035PubMedGoogle Scholar
  62. 62.
    Reichel H, Koeffler HP, Tobler A, Norman AW (1987) 1 alpha,25-Dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci U S A 84:3385–3389PubMedCrossRefGoogle Scholar
  63. 63.
    Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O’Garra A (2001) 1Alpha,25-dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 167:4974–4980PubMedGoogle Scholar
  64. 64.
    Gorman S, Kuritzky LA, Judge MA et al (2007) Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+ CD25+ cells in the draining lymph nodes. J Immunol 179:6273–6283PubMedGoogle Scholar
  65. 65.
    Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM (2008) Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. J Pharmacol Exp Ther 324:23–33PubMedCrossRefGoogle Scholar
  66. 66.
    Yu S, Cantorna MT (2008) The vitamin D receptor is required for iNKT cell development. Proc Natl Acad Sci U S A 105:5207–5212PubMedCrossRefGoogle Scholar
  67. 67.
    Broux B, Pannemans K, Zhang X et al (2012) CX(3)CR1 drives cytotoxic CD4(+)CD28(−) T cells into the brain of multiple sclerosis patients. J Autoimmun 38:10–19PubMedCrossRefGoogle Scholar
  68. 68.
    Luckey D, Bastakoty D, Mangalam AK (2011) Role of HLA class II genes in susceptibility and resistance to multiple sclerosis: studies using HLA transgenic mice. J Autoimmun 37:122–128PubMedCrossRefGoogle Scholar
  69. 69.
    Moroni L, Bianchi I, Lleo A (2012) Geoepidemiology, gender and autoimmune disease. Autoimmun Rev 11:A386–A392PubMedCrossRefGoogle Scholar
  70. 70.
    Sellner J, Kraus J, Awad A, Milo R, Hemmer B, Stuve O (2011) The increasing incidence and prevalence of female multiple sclerosis–a critical analysis of potential environmental factors. Autoimmun Rev 10:495–502PubMedCrossRefGoogle Scholar
  71. 71.
    Soilu-Hanninen M, Airas L, Mononen I, Heikkila A, Viljanen M, Hanninen A (2005) 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult Scler 11:266–271PubMedCrossRefGoogle Scholar
  72. 72.
    Correale J, Ysrraelit MC, Gaitan MI (2009) Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain 132:1146–1160PubMedCrossRefGoogle Scholar
  73. 73.
    Soilu-Hanninen M, Laaksonen M, Laitinen I, Eralinna JP, Lilius EM, Mononen I (2008) A longitudinal study of serum 25-hydroxyvitamin D and intact parathyroid hormone levels indicate the importance of vitamin D and calcium homeostasis regulation in multiple sclerosis. J Neurol Neurosurg Psychiatry 79:152–157PubMedCrossRefGoogle Scholar
  74. 74.
    van der Mei IA, Ponsonby AL, Dwyer T et al (2007) Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 254:581–590PubMedCrossRefGoogle Scholar
  75. 75.
    Smolders J, Menheere P, Kessels A, Damoiseaux J, Hupperts R (2008) Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Mult Scler 14:1220–1224PubMedCrossRefGoogle Scholar
  76. 76.
    Hiremath GS, Cettomai D, Baynes M et al (2009) Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler 15:735–740PubMedCrossRefGoogle Scholar
  77. 77.
    Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A (2006) Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296:2832–2838PubMedCrossRefGoogle Scholar
  78. 78.
    Kragt J, van Amerongen B, Killestein J et al (2009) Higher levels of 25-hydroxyvitamin D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 15:9–15PubMedCrossRefGoogle Scholar
  79. 79.
    de Boer IH, Sachs MC, Cleary PA et al. (2012) Circulating vitamin D metabolites and kidney disease in type 1 diabetes. J Clin Endocrinol Metab 97(12):4780–4788Google Scholar
  80. 80.
    Borkar VV, Devidayal, Verma S, Bhalla AK (2010) Low levels of vitamin D in North Indian children with newly diagnosed type 1 diabetes. Pediatr Diabetes 11:345–350PubMedCrossRefGoogle Scholar
  81. 81.
    Singh DK, Winocour P, Summerhayes B, Viljoen A, Sivakumar G, Farrington K (2009) Are low erythropoietin and 1,25-dihydroxyvitamin D levels indicative of tubulo-interstitial dysfunction in diabetes without persistent microalbuminuria? Diabetes Res Clin Pract 85:258–264PubMedCrossRefGoogle Scholar
  82. 82.
    Bener A, Alsaied A, Al-Ali M et al (2009) High prevalence of vitamin D deficiency in type 1 diabetes mellitus and healthy children. Acta Diabetol 46:183–189PubMedCrossRefGoogle Scholar
  83. 83.
    Littorin B, Blom P, Scholin A et al (2006) Lower levels of plasma 25-hydroxyvitamin D among young adults at diagnosis of autoimmune type 1 diabetes compared with control subjects: results from the nationwide Diabetes Incidence Study in Sweden (DISS). Diabetologia 49:2847–2852PubMedCrossRefGoogle Scholar
  84. 84.
    Bogaczewicz J, Sysa-Jedrzejowska A, Arkuszewska C et al (2012) Vitamin D status in systemic lupus erythematosus patients and its association with selected clinical and laboratory parameters. Lupus 21:477–484PubMedCrossRefGoogle Scholar
  85. 85.
    Kim HA, Sung JM, Jeon JY, Yoon JM, Suh CH (2011) Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus. Rheumatol Int 31:1189–1194PubMedCrossRefGoogle Scholar
  86. 86.
    Amital H, Szekanecz Z, Szucs G et al (2010) Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis 69:1155–1157PubMedCrossRefGoogle Scholar
  87. 87.
    Wright TB, Shults J, Leonard MB, Zemel BS, Burnham JM (2009) Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J Pediatr 155:260–265PubMedCrossRefGoogle Scholar
  88. 88.
    Borba VZ, Vieira JG, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M (2009) Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporos Int 20:427–433PubMedCrossRefGoogle Scholar
  89. 89.
    Ruiz-Irastorza G, Egurbide MV, Olivares N, Martinez-Berriotxoa A, Aguirre C (2008) Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford) 47:920–923CrossRefGoogle Scholar
  90. 90.
    Cantorna MT (2006) Vitamin D and its role in immunology: multiple sclerosis, and inflammatory bowel disease. Prog Biophys Mol Biol 92:60–64PubMedCrossRefGoogle Scholar
  91. 91.
    Nordvik I, Myhr KM, Nyland H, Bjerve KS (2000) Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 102:143–149PubMedCrossRefGoogle Scholar
  92. 92.
    Achiron A, Barak Y, Miron S, Izhak Y, Faibel M, Edelstein S (2003) Alfacalcidol treatment in multiple sclerosis. Clin Neuropharmacol 26:53PubMedCrossRefGoogle Scholar
  93. 93.
    Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC (2005) A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 76:1294–1296PubMedCrossRefGoogle Scholar
  94. 94.
    Li X, Liao L, Yan X et al (2009) Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 25:411–416PubMedCrossRefGoogle Scholar
  95. 95.
    Pitocco D, Crino A, Di Stasio E et al (2006) The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset type 1 diabetes (IMDIAB XI). Diabet Med 23:920–923PubMedCrossRefGoogle Scholar
  96. 96.
    Ruiz-Irastorza G, Gordo S, Olivares N, Egurbide MV, Aguirre C (2010) Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity, and damage. Arthritis Care Res (Hoboken) 62:1160–1165CrossRefGoogle Scholar
  97. 97.
    Antico A, Tampoia M, Tozzoli R, Bizzaro N (2012) Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmun Rev 12:127–136PubMedCrossRefGoogle Scholar
  98. 98.
    Roy E, Leduc M, Guegan S et al (2011) Specific maternal microchimeric T cells targeting fetal antigens in beta cells predispose to auto-immune diabetes in the child. J Autoimmun 36:253–262PubMedCrossRefGoogle Scholar
  99. 99.
    Bogdanos DP, Smyk DS, Rigopoulou EI et al (2012) Twin studies in autoimmune disease: genetics, gender and environment. J Autoimmun 38:J156–J169PubMedCrossRefGoogle Scholar
  100. 100.
    Staples JA, Ponsonby AL, Lim LL, McMichael AJ (2003) Ecologic analysis of some immune-related disorders, including type 1 diabetes, in Australia: latitude, regional ultraviolet radiation, and disease prevalence. Environ Health Perspect 111:518–523PubMedCrossRefGoogle Scholar
  101. 101.
    Hypponen E, Laara E, Reunanen A, Jarvelin MR, Virtanen SM (2001) Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 358:1500–1503PubMedCrossRefGoogle Scholar
  102. 102.
    Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y (2012) Systemic lupus erythematosus one disease or many? Autoimmun Rev 11:593–595PubMedCrossRefGoogle Scholar
  103. 103.
    Borchers AT, Naguwa SM, Shoenfeld Y, Gershwin ME (2010) The geoepidemiology of systemic lupus erythematosus. Autoimmun Rev 9:A277–A287PubMedCrossRefGoogle Scholar
  104. 104.
    Fu SM, Deshmukh US, Gaskin F (2011) Pathogenesis of systemic lupus erythematosus revisited 2011: end organ resistance to damage, autoantibody initiation and diversification, and HLA-DR. J Autoimmun 37:104–112PubMedCrossRefGoogle Scholar
  105. 105.
    Lehmann P, Homey B (2009) Clinic and pathophysiology of photosensitivity in lupus erythematosus. Autoimmun Rev 8:456–461PubMedCrossRefGoogle Scholar
  106. 106.
    Breslin LC, Magee PJ, Wallace JM, McSorley EM (2011) An evaluation of vitamin D status in individuals with systemic lupus erythematosus. Proc Nutr Soc 70:399–407PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Chen-Yen Yang
    • 1
  • Patrick S. C. Leung
    • 1
  • Iannis E. Adamopoulos
    • 1
    • 2
  • M. Eric Gershwin
    • 1
  1. 1.Division of Rheumatology, Allergy and Clinical ImmunologyUniversity of California at Davis School of MedicineDavisUSA
  2. 2.Institute of Pediatric and Regenerative MedicineShriners Hospital for Northern CaliforniaSacramentoUSA

Personalised recommendations